Affimed N.V. | CIK:0001608390 | 3

  • Filed: 3/20/2018
  • Entity registrant name: Affimed N.V. (CIK: 0001608390)
  • Generator: QXi
  • SEC filing page: http://www.sec.gov/Archives/edgar/data/1608390/000095010318003510/0000950103-18-003510-index.htm
  • XBRL Instance: http://www.sec.gov/Archives/edgar/data/1608390/000095010318003510/afmd-20171231.xml
  • XBRL Cloud Viewer: Click to open XBRL Cloud Viewer
  • EDGAR Dashboard: https://edgardashboard.xbrlcloud.com/edgar-dashboard/?cik=0001608390
  • Open this page in separate window: Click
  • ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory

    Costs incurred related to research activities are expensed in the period incurred. Costs incurred on development projects are recognized as intangible assets beginning on the date it can be established that it is probable that future economic benefits attributable to the asset will flow to the Company considering its technological and commercial feasibility. Given the current stage of the development of the Company’s product candidates and technologies, no development expenditures have yet been capitalized. Intellectual property-related costs for patents are part of the expenditure for the research and development projects. Therefore, registration costs for patents are expensed when incurred as long as the research and development project concerned does not meet the criteria for capitalization.